Ken Griffin Praxis Precision Medicines, Inc. Call Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 14, 2023	BUY	$0.87 - $1.71 $10,092 - $19,836	11,600 Added 109.43%	22,200 $37,000
Q2 2023 Aug 14, 2023	BUY	$0.83 - $1.18 $1,162 - $1,652	1,400 Added 15.22%	10,600 $12,000
Q1 2023 May 15, 2023	BUY	$0.8 - $4.98 $6,000 - $37,350	7,500 Added 441.18%	9,200 $7,000
Q4 2022 Feb 14, 2023	SELL	$1.88 - $2.49 $256,995 - $340,383	-136,700 Reduced 98.77%	1,700 $4,000
Q3 2022 Nov 14, 2022	SELL	$2.5 - $4.77 $130,000 - $248,039	-52,000 Reduced 27.31%	138,400 $314,000

75K

Ticker PRAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,576,100
Market Cap $1.79B
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.